The European Patent Office (EPO) has granted patent EP3880216B1, titled 'Methods for Treating Cancer with Manufactured Cells'. This patent, granted on March 18, 2026, relates to novel methods for cancer treatment utilizing manufactured cells, with inventors listed as Daniel Harding Fowler. The patent is designated for use in multiple European states.

This patent grant signifies a new intellectual property right in the field of cancer therapeutics. Companies involved in biotechnology, pharmaceutical development, and medical device manufacturing should review the patent's claims to understand potential impacts on their research, development, and commercialization activities. While this is a patent grant and not a regulatory rule with compliance deadlines, it establishes exclusive rights that may affect market access and competitive landscapes.